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BRIEF REPORT
Immunostimulatory membrane proteins potentiate H. pylori-induced 
carcinogenesis by enabling CagA translocation
Matthew G. Vargaa, Cecily R. Woodb, Julia Buttc, Mackenzie E. Ryand, Wei-Cheng Youe, Kaifeng Pane, 
Tim Waterboerc, Meira Eppleinf, and Carrie L. Shaffer b,d,g
aDepartment of Epidemiology, Lineberger Comprehensive Cancer Center and Gillings School of Global Public Health, University of North 
Carolina, Chapel Hill, NC, USA; bDepartment of Veterinary Science, University of Kentucky, Lexington, KY, USA; cInfections and Cancer 
Epidemiology, German Cancer Research Center, Heidelberg, Germany; dDepartment of Microbiology, Immunology, and Molecular Genetics, 
University of Kentucky, Lexington, KY, USA; eDepartment of Cancer Epidemiology, Peking University Cancer Hospital and Institute, Beijing, 
China; fDepartment of Population Health Sciences and Duke Cancer Institute, Cancer Control and Population Sciences Program, Duke 
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ABSTRACT
Infection with Helicobacter pylori is the single greatest risk factor for developing gastric adenocar-
cinoma. In prospective, population-based studies, seropositivity to the uncharacterized H. pylori 
proteins Hp0305 and Hp1564 was significantly associated with cancer risk in East Asia. However, the 
mechanism underlying this observation has not been elucidated. Here, we show that Hp0305 and 
Hp1564 act in concert with previously ascribed H. pylori virulence mechanisms to orchestrate 
cellular alterations that promote gastric carcinogenesis. In samples from 546 patients exhibiting 
premalignant gastric lesions, seropositivity to Hp0305 and Hp1564 was significantly associated with 
increased gastric atrophy across all stomach conditions. In vitro, depletion of Hp0305 and Hp1564 
significantly reduced levels of gastric cell-associated bacteria and markedly impaired the ability of 
H. pylori to stimulate pro-inflammatory cytokine production. Remarkably, our studies revealed that 
Hp1564 is required for translocation of the oncoprotein CagA into gastric epithelial cells. Our data 
provide experimental insight into the molecular mechanisms governing novel H. pylori pathogeni-
city factors that are strongly associated with gastric disease and highlight the potential of Hp0305 
and Hp1564 as robust molecular tools that can improve identification of individuals that are highly 
susceptible to gastric cancer. We demonstrate that Hp0305 and Hp1564 augment H. pylori- 
mediated inflammation and gastric cancer risk by promoting key bacteria-gastric cell interactions 
that facilitate delivery of oncogenic microbial cargo to target cells. Thus, therapeutically targeting 
microbial interactions driven by Hp0305/Hp1564 may enable focused H. pylori eradication strate-
gies to prevent development of gastric malignancies in high-risk populations.
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Introduction
Infection with the gastric pathogen Helicobacter pylori 
is the single greatest risk factor for the development of 
gastric adenocarcinoma and is attributable for over 
80% of the gastric cancer burden.1 Gastric adenocar-
cinoma is the third leading cause of cancer-related 
death worldwide, with over half of all incident gastric 
cancers occurring within East Asia.2 While the global 
prevalence of H. pylori exceeds 50%, less than 3% of 
infected individuals will develop adenocarcinoma.1 
Therefore, due to the high incidence of this bacterium 
in global populations and the relatively low risk of 
carcinogenesis, mass eradication strategies are neither 
advisable nor feasible. Targeted eradication strategies 
in highly susceptible populations have been shown to 
reduce gastric cancer risk.3,4 Thus, identifying specific 
predictive factors could enable the development of 
powerful screening modalities to pinpoint high-risk 
populations that would benefit from targeted eradica-
tion and screening strategies.
The H. pylori cag pathogenicity island (cag PAI) is 
a strain-specific virulence factor that augments cancer 
risk.5,6 The cag PAI encodes a type IV secretion system 
(cag T4SS) that facilitates the delivery of peptidogly-
can, nucleic acids, lipid metabolites, and the oncopro-
tein CagA into host cells.7–9 The majority of people inf 
ected by H. pylori harboring the cag T4SS do not 
develop cancer,1,10,11 suggesting that other bacterial co  
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nstituents affect disease risk. Previously, we employed 
a serologic H. pylori biomarker panel to demonstrate 
that seropositivity to two uncharacterized H. pylori 
proteins encoded by Hp0305 and Hp1564 were asso-
ciated with a fourfold increase in the odds of gastric 
cancer incidence in a consortium of eight prospective 
cohorts from East Asian populations.12 These findings 
were then validated as markers of gastric precancerous 
lesions in an independent study population from 
a high-risk region of Linqu County, China.13 Antibo 
dy response to the dual-positivity of Hp0305 and Hp 
1564 (referred to as OMP in previous studies) was 
superior at predicting incident gastric cancer risk as 
well as prevalent precancerous gastric lesions com-
pared to detecting H. pylori alone or the secreted 
oncoprotein CagA.12,13 Despite the observed associa-
tions of Hp0305 and Hp1564 with cancer risk, the 
mechanism by which these proteins influence carci-
nogenesis remains unknown. Thus, we sought to elu-
cidate the role of these proteins in H. pylori-mediated 
carcinogenesis in an effort to delineate promising bac 
terial factors that could be therapeutically targeted in 
novel precise intervention strategies.
Materials and methods
Linqu County study population
Serum samples analyzed for antibody responses to 
Hp0305 and Hp1564 as well as levels of pepsinogen 
I and II were obtained from the Linqu County inter 
vention trial as described previously.13,14 Briefly, in 
2002, an intervention trial was established in Linqu 
County, Shandong Province, China, to compare the 
effect of H. pylori treatment and selective COX-2 
inhibitors on precancerous gastric lesions. In total 
2,813 residents aged 35–64 were recruited from 12 
randomly selected villages in Linqu County. At 
baseline entry into the study, participants complet 
ed a standard structured questionnaire and provid 
ed a blood sample. Participants were also screened 
by upper endoscopy15 for presence of superficial 
gastritis (SG), chronic atrophic gastritis (CAG), int 
estinal metaplasia (IM), indefinite dysplasia (Ind 
DYS), dysplasia (DYS), and cancer, following the 
criteria of the Updated Sydney System15 and the 
Padova International Classification.16 A written in 
formed consent was obtained from each participant 
and the study was approved by the Institutional 
Review Board of Peking University Cancer Hospi 
tal (2016KT90).
For the initial study of validating H. pylori anti-
body biomarkers associated with precancerous gas-
tric lesions, a total of 1,402 individuals screened by 
upper endoscopy at baseline were included.13 Of 
those individuals, valid pepsinogen I and II levels 
were available for a subset of participants, thus, the 
present study included only those 546 individuals 
(226 controls and 320 cases).
Measurement of serum antibody responses to 
Hp0305 and Hp1564
Antibody responses to H. pylori hypothetical pro-
teins Hp0305 and Hp1564 were measured as part of 
a larger multiplex serology panel including in total 
13 H. pylori proteins as described previously.13,17 
Briefly, H. pylori proteins were recombinantly 
expressed as Glutathione-S-transferase (GST)-tag 
fusion proteins in Escherichia coli BL21 and affi-
nity-purified on glutathione-coated fluorescently 
labeled polystyrene beads (Luminex Corp.). A mix 
ture of the differently labeled and antigen-loaded 
beads was then incubated with serum to allow 
binding of serum antibodies to the H. pylori pro-
teins. Bound serum antibodies were detected by 
a biotin-labeled anti-human IgM/IgA/IgG second-
ary antibody and Streptavidin-R-phycoerythrin. 
A Luminex 200 analyzer (Luminex Corp.) then 
distinguished between the bead type and consequ 
ently the bound antigen as well as quantified the 
amount of bound serum antibody as median fluor-
escence intensity (MFI) of 100 beads per type mea-
sured. Antigen-specific cutoffs were determined as 
described in Epplein et al., 2018.13
Detection of pepsinogen I and II in serum
Pepsinogen I and II levels in serum were deter-
mined by pepsinogen I and II enzyme-linked 
immunosorbent assay (ELISA) (Eagle Biosciences) 
according to manufacturer’s instructions and as 
described previously.13 The pepsinogen I and II 
concentration (ng/ml) in each sample was deter-
mined by provided assay standards to obtain a plate 
specific standard curve. A ratio of pepsinogen 
I over II was calculated for each sample for further 
analysis.
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Statistical analyses
As only a few individuals presented with normal 
gastric mucosa, study participants with superficial 
gastritis (SG) were chosen as the referent group. 
Thus, the distribution of demographic characteris-
tics among individuals with precancerous lesions 
(CAG, IM, Ind Dys, and Dys) was compared to 
individuals with SG by Chi-squared test for catego-
rical variables and Student’s t-test for continuous 
variables. The H. pylori seromarker of combined 
Hp0305 and Hp1564 status was applied as defined 
in Epplein et al., 201813 as being either dual sero-
negative for both proteins, seropositive for either 
Hp0305 or Hp1564, or dual seropositive for both 
Hp0305 and Hp1564. The pepsinogen I/II ratio as 
a continuous variable was compared between the th 
ree Hp0305/Hp1564 sero-statuses by Wilcoxon ra 
nk-sum test, either in the overall study population 
or separately within each stomach condition group 
(SG, CAG, IM, Ind Dys, or Dys). A two-sided p- 
value<0.05 was considered statistically significant.
For in vitro assays, IL-8 production induced by 
H. pylori mutants was compared to corresponding 
IL-8 secretion levels induced by the WT strain by 
one-way ANOVA with Dunnett’s post-hoc correc-
tion for multiple comparisons. For experiments 
evaluating levels of adherent and internalized bac-
teria, enumerated colony forming units (CFUs) for 
each mutant were compared to the WT strain by 
two-tailed Mann-Whitney test. For qPCR studies, 
transcript levels produced by the cagX mutant were 
compared to the corresponding transcript levels 
produced by WT by unpaired two-tailed t-test.
Bacterial strains and culture conditions
Helicobacter pylori 26695 (ATCC) and its isogenic 
derivatives were maintained on trypticase soy agar 
plates supplemented with 5% sheep blood (BD 
Biosciences) as previously described.18 Overnight 
cultures were grown in Brucella broth supplemen-
ted with 5% FBS at 37°C with 5% CO2. E. coli DH5α 
was grown on Luria-Bertani (LB) agar plates or in 
LB liquid medium with appropriate antibiotics 
overnight as needed for general cloning and plas-
mid propagation.
Generation of H. pylori isogenic mutant derivatives
H. pylori mutants were generated as previously 
described.18 Briefly, H. pylori was transformed with 
a suicide plasmid in which the coding region of the 
target gene was replaced by either a kanamycin 
resistance cassette (Hp0305) or a chloramphenicol 
resistance cassette (Hp1564) and homologous flank-
ing DNA sequences 500 base pairs (bp) up- and 
downstream of the target locus. Colonies resistant 
to kanamycin (12.5 μg/ml) or chloramphenicol 
(10 μg/ml) were PCR-verified to confirm insertion 
of the resistance cassette into the appropriate locus 
in the same orientation as operon transcription. 
Generation of the Hp0305/Hp1564 double mutant 
was constructed by transformation of the Hp1564:: 
cat derivative with the Hp0305::kan plasmid. 
Transformants were selected based on dual resis-
tance to kanamycin and chloramphenicol, and 
gene deletion was verified by PCR targeting the 
insertion locus with comparison to the WT strain.
To complement mutants in cis at the ureA hetero-
logous chromosomal locus, we used plasmids derived 
from pAD1.18 Plasmids were constructed to permit 
expression of C-terminal hemagglutinin (HA) epi-
tope-tagged Hp0305 (pAD1-CamR) and Hp1564 
(pAD1-KanR). Plasmid sequences were confirmed by 
sequencing, and constructs were used to transform 
Hp0305 and Hp1564 mutants, respectively. Insertion 
of complementation constructs into the ureA locus 
was confirmed by PCR amplification, and expression 
of the Hp0305-HA and Hp1564-HA epitope-tagged 
proteins was verified by immunoblotting using mono-
clonal anti-HA antibodies.
Generation of TEM-CagA reporter strains
TEM-CagA expression strains were generated essen 
tially as previously described.19 Briefly, a synthetic 
gene construct was generated comprising 500 bp up 
stream of the endogenous cagA promoter, the E. coli 
blaM gene (encoding the TEM-1 β-lactamase) lack-
ing the N-terminal signal sequence under the con-
trol of the native cagA promoter, and 500 bp do 
wnstream of the cagA start codon. The synthetic TE 
M-CagA construct was transformed into the cagA:: 
cat-rdxA strain,18 and counterselection on metroni-
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dazole (15 μg/ml) was performed to select positive 
clones expressing TEM-CagA. Insertion of the 
TEM-CagA construct into the cagA locus was ver-
ified by PCR and immunoblot analysis probing for 
TEM-CagA production (approximately 160 kDa vs 
140 kDa for WT CagA). A TEM-CagA cagE mutant 
was generated as previously described18 via trans-
formation with a suicide vector in which the cagE 
coding region was replaced with a kanamycin resis-
tance cassette transcribed in the same direction as 
the operon. TEM-CagA cagE mutants were selected 
by resistance to kanamycin, and deletion of cagE 
was verified by PCR. To generate the TEM-CagA 
Hp1564 mutant, the verified TEM-CagA strain was 
transformed with the Hp1564::cat construct and was 
selected on chloramphenicol as described for muta-
genesis of the WT strain. Disruption of the Hp1564 
locus was verified by PCR. The corresponding 
Hp1564-HA complemented strain was generated 
by transformation of the TEM-CagA Hp1564 
mutant strain with the pAD-Hp1564-HA construct 
and selection on kanamycin. Integration of the 
Hp1564-HA expression construct was verified by 
PCR and immunoblot analysis probing for 
C-terminal HAepitope-tagged Hp1564.
Human cell culture
AGS human gastric epithelial cells (ATCC CRL- 
1739) were cultured in RPMI 1640 medium supple-
mented with 10% fetal bovine serum (FBS), 2 mM 
L-glutamine, and 10 mM HEPES in the presence of 
5% CO2 at 37°C. Primary adult human gastric 
epithelial cells (Cell Biologics H-6039) were propa-
gated in human epith 
elial cell medium supplemented with ITS, EGF, 
hydrocortisone, L-glutamine, and 5% FBS (Cell 
Biologics H662). HEK293-hTLR9 and the corre-
sponding parental HEK293 tlr9-/- reporter cell 
lines (InvivoGen) were grown in the presence of 5% 
CO2 in DMEM supplemented with 10% heat-inac 
tivated FBS and 2 mM L-glutamine.
IL-8 quantitation
Secretion of IL-8 by AGS cells co-cultured with 
H. pylori or its isogenic derivatives was determined 
using the human CXCL8 ELISA (R&D Systems). 
Briefly, AGS cells were infected with H. pylori or 
each isogenic mutant for 4.5 h at a multiplicity of 
infection (MOI) of 100. Cell-free supernatants were 
collected and analyzed as previously described.18 
Biological replicate experiments were performed 
a minimum of at least three times.
Immunoblot analysis of cag T4SS proteins
H. pylori and its derivatives were propagated on 
TSAII plates supplemented with 5% sheep blood 
(BD Biosciences) for 24 or 48 h, or in Brucella broth 
supplemented with 5% FBS for 16 hours. Bacterial 
cultures were normalized to an OD600 of 1.0 prior to 
lysis in 2X SDS buffer (Bio-Rad). Standardized sam-
ples were resolved by SDS-PAGE, transferred to 
nitrocellulose membranes (Bio-Rad), and analyzed 
by immunoblotting using either α-CagA or α-CagY 
polyclonal antisera.
CagA translocation assays
CagA translocation into AGS cells was performed as 
described previously.18 Briefly, AGS cells were 
infected at an MOI of 100 in triplicate in for 6 h 
prior to at least three washes in 1X PBS to remove 
non-adherent bacteria. AGS cells were lysed in buffer 
containing 1% NP-40 with cOmplete™ mini EDTA- 
free protease inhibitor (Roche) and PhosSTOP phos-
phatase inhibitor (Roche). The soluble fraction was 
separated on a 7.5% gel (Bio-Rad) for immunoblot 
analysis probed by an anti-phosphotryosine antibody 
(α-PY99, Santa Cruz). Membranes were subsequently 
probed for total CagA (α-CagA, Santa Cruz), β- 
tubulin (Invitrogen), and H. pylori outer membrane 
protein (α-OMP, Santa Cruz). CagA translocation 
assays were performed at least four times per strain, 
and the ratio of translocated CagA (pY-CagA) to 
total CagA was determined by densitometry analysis 
for each strain in biological replicate experiments 
using ImageJ as previously described.18
TEM-CagA translocation assays
TEM-CagA translocation was assayed as previously 
described.19 Briefly, AGS cells were infected by WT 
TEM-CagA or isogenic mutant strains for 2.5 h. 
After infection, cells were loaded with the fluores-
cent substrate CCF4-AM in loading solution 
(LiveBLAzer-FRET B/G loading kit, Invitrogen) 
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supplemented with 1 mM probenecid (Sigma). For 
fluorescence quantification by plate reader assay, 
infected cells were incubated with loading solution 
at in the dark for 2.5 h, and fluorescence was mea-
sured with a Synergy H1 hybrid multi-mode plate 
reader (BioTek) using an excitation wavelength of 
410 nm. Emission was detected at 450 nm (blue 
fluorescence) and 520 nm (green fluorescence). 
Levels of CagA translocation were defined as the 
ratio of emission at 450 nm(sample-blank) divided by 
the emission at 520 nm(sample-blank), where the blank 
wells contained only CCF4-AM loading solution in 
cell culture media in the absence of AGS cells and 
bacteria. Relative CagA translocation is expressed 
as the ratio of 410em/520em, and data are expressed 
as the fold change over uninfected controls.
TLR9 activation assays
HEK293 cells expressing a human TLR9 reporter 
construct (hTLR9) or parental Null1 cells 
(Invivogen) were infected in quadruplicate over-
night at an MOI of 100 with H. pylori 26695 or 
isogenic mutant strains as previously described.8 
TLR9 activation was quantified by measuring secr 
eted embryonic alkaline phosphatase (SEAP) repor 
ter activity in cell culture supernatants by Quanti 
Blue reagent (Invivogen). TLR9 activation was nor-
malized to SEAP levels produced by infected tlr9-/- 
parental cells, and is expressed as the fold-change 
over mock-infected controls. A minimum of three 
biological replicate experiments were performed 
for each strain.
Bacterial adherence and internalization assays
H. pylori or its isogenic derivatives were co-cultured 
with AGS gastric epithelial cells or HEK293-hTLR9 
cells as described for IL-8 induction assays.18 After 
4 h of infection, cell culture media was aspirated and 
wells were washed three times with PBS to remove 
non-adherent bacteria. A subset of wells used to eval 
uate total adherent and intracellular bacteria were 
replenished with fresh cell culture media. Intracellu 
lar levels of H. pylori were assessed by treating the 
remainder of the wells with cell culture media sup-
plemented with gentamycin (100 μg/mL) and incu-
bation for 1 h at 37°C with 5% CO2. Media was 
removed, and wells were washed three times in 
sterile PBS to remove residual media and gentami-
cin. Infected wells were mechanically lysed in PBS, 
and samples were serially diluted on blood agar for 
colony enumeration. A minimum of three biological 
replicate experiments were performed in triplicate 
for each bacterial strain.
RNA isolation and real-time quantitative PCR (qPCR)
To assess transcript levels of target genes in response to 
host cell contact, adult primary gastric epithelial cells 
were either uninfected or co-cultured with H. pylori 
26695 or isogenic derivatives for 4 to 6 h. Cells were 
washed with sterile PBS three times before total RNA 
isolation by the Direct-Zol Miniprep Plus kit (Zymo 
Research) following the manufacturer’s protocol. Total 
RNA was digested with Turbo DNase I (Invitrogen) 
prior to cDNA synthesis using the iScript cDNA synth-
esis kit (Bio-Rad) from 500 ng of total DNA-free RNA 
template. cDNA was diluted 1:20, and qPCR was per-
formed using TaqMan MGB chemistry as previously 
described.18 To assess levels of target gene mRNA in 
planktonic culture, H. pylori 26695 and corresponding 
derivative strains were grown overnight in Brucella 
broth supplemented with 5% FBS, and RNA was pre-
pared as described for co-culture samples. cDNA was 
generated from 500 ng of total bacterial DNA-free RNA 
template. As a control, equivalent concentrations of 
DNA-free RNA from each sample were analyzed by 
qPCR in parallel. The relative abundance of Hp0305 
and Hp1564 transcripts produced when bacteria were 
co-cultured with primary gastric cells was calculated 
using the ΔΔCT method, with each transcript normal-
ized to the abundance of the multiplexed gyrB endo-
genous control, and compared to normalized transcript 
levels produced by H. pylori in the absence of host cell 
contact.
Results
H. pylori Hp0305/Hp1564 seropositivity and 
decreased pepsinogen I/II ratios are associated with 
precancerous gastric lesions
Among individuals with precancerous gastric lesions, 
only those with Ind Dys were more likely to be men 
and current smokers as compared to the reference 
group of individuals with SG (Table 1). However, for 
all precancerous lesion types the seroprevalence of 
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H. pylori proteins Hp0305/Hp1564 dual-positivity was 
higher (CAG: 33%, IM: 65%, Ind Dys: 54%, Dys: 55%) 
than among individuals with SG (17%) (Table 1). 
A low pepsinogen I/II ratio is an established serum 
marker for presence of CAG in the stomach and 
associated with stomach cancer risk. Therefore, we 
assessed whether pepsinogen I/II ratios were also asso-
ciated with Hp0305/Hp1564 seropositivity in our 
study population, and determined whether these para-
meters varied with type of premalignant stomach con-
dition, i.e. SG, CAG, IM, Ind Dys, and Dys (Figure 1). 
Indeed, the pepsinogen I/II ratio was significantly 
lower in Hp0305/Hp1564 dual seropositive indivi-
duals compared to dual-negative individuals in the 
overall study population as well as in all precancerous 
lesions (CAG, IM, Ind Dys, and Dys). Thus, Hp0305/ 
Hp1564 dual-positivity was more common among 
individuals with precancerous lesions compared to 
SG, and was concordantly associated with a lower 
pepsinogen I/II ratio, indicating a greater severity of 
gastritis among individuals with a demonstrated 
immune response to both H. pylori antigens.
Hp0305 and Hp1564 influence IL-8 cytokine 
secretion by gastric epithelial cells
H. pylori-induced carcinogenesis primarily results from 
prolonged inflammation of the gastric mucosa. One 
marker of H. pylori-induced inflammation is elevated 
levels of IL-8.20 Therefore, we assessed the ability of strain 
26695 (used to generate the multiplex serology panel 
employed in this study) and corresponding mutant 
strains lacking either Hp0305, Hp1564, or both 
Hp0305/Hp1564 to induce cag T4SS-dependent IL-8 
secretion in cultured, immortalized gastric cells. 
Compared to uninfected controls or cells infected with 
a cagX mutant strain defective in cag T4SS activity,21 we 
observed a significant reduction in IL-8 secretion when 
gastric epithelial cells were co-cultured with either 
Hp0305 (p < .001) or Hp1564 (p < .0001), an effect that 
was further compounded by co-culture with the double 
knockout Hp0305/Hp1564 (p < .0001) (Figure 2(a)). 
Complementation of the Hp0305 and Hp1564 mutants 
with Hp0305-HA or Hp1564-HA constructs, respec-
tively, restored IL-8 secretion to levels indistinguishable 
from WT (Figure 2(a)), confirming a direct role of these 
proteins in cag T4SS function. To recapitulate the gastric 
niche, we also co-cultured H. pylori strains with adult 
primary gastric epithelial cells (Figure 2(b)). As expected, 
a cagX-deficient mutant induced significantly less IL-8 
secretion compared to the parental strain; however, only 
the Hp0305/Hp1564 double mutant exhibited significant 
defects in eliciting IL-8 responses compared to either 
single mutant strain (Figure 2(b)). Together, these results 
suggest that Hp0305 and Hp1564 are associated with cag 
T4SS-dependent IL-8 synthesis and secretion in vitro, 
which may contribute to the increased oncogenicity 
observed in our population-based studies.
Hp1564 is required for translocation of the 
oncoprotein CagA into epithelial cells
As all known cag T4SS phenotypes require direct host 
cell contact, we next performed gentamicin protection 
assays to assess both bacterial adherence and interna-
lization into host gastric cells. Compared to the WT 
Table 1. Demographic characteristics of the study population, Linqu County, Shandong Province, China, 2002–2004.
Referent group Gastric precancerous lesions
SG (n = 60) CAG (n = 166) p- 
value*
IM (n = 142) p- 
value*
Ind Dys (n = 116) p- 
value*
Dys 
(n = 62)
p- 
value*
Sex, n (%)
Female 32 (53) 98 (59) 79 (56) 43 (37) 28 (45)
Male 28 (47) 68 (41) 0.444 63 (44) 0.764 73 (63) 0.039 34 (55) 0.367
Age, mean (SD) 49 (8) 49 (6) 0.582 50 (6) 0.519 50 (7) 0.602 50 (7) 0.444
Current smoker, n (%)
No 35 (58) 113 (68) 92 (65) 47 (41) 31 (50)
Yes 25 (42) 53 (32) 0.174 50 (35) 0.386 69 (59) 0.025 31 (50) 0.356
HP0305/HP1564, n (%)
Dual-negative 37 (62) 74 (45) 15 (11) 25 (22) 12 (19)
Either/or 13 (22) 38 (23) 34 (24) 28 (24) 16 (26)
Dual-positive 10 (17) 54 (33) 0.038 93 (65) <0.001 63 (54) <0.001 34 (55) <0.001
SG, superficial gastritis; CAG, chronic atrophic gastritis; IM, Intestinal metaplasia; Ind Dys, Indefinite Dysplasia; Dys, Dysplasia; 
*Compared to superficial gastritis, Chi-squared test for categorical variables, Student’s test for continuous variables, p-value<0.05 considered 
statistically significant (marked in bold font).
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strain, Hp1564 displayed significantly reduced levels of 
bacterial internalization (p = .04), while the Hp0305/ 
Hp1564 double mutant displayed significantly 
reduced adherence and internalization (p < .001 for 
both metrics) when co-cultured with AGS gastric 
epithelial cells (Figure 2(c)).
H. pylori strains that harbor the cag T4SS have the 
capacity to translocate the bacterial oncoprotein CagA 
directly into gastric epithelial cells, and are associated 
with a higher gastric cancer risk.11 Therefore, we next 
sought to determine whether Hp0305 and/or Hp1564 
were required for CagA delivery to gastric cells. Under 
standard growth conditions, deletion of Hp0305 and/or 
Hp1564 did not significantly alter levels of CagA or the 
cag T4SS structural component CagY compared to the 
WT or complemented strains (Figure 2(d)). However, 
we determined that loss of Hp1564, but not Hp0305, 
significantly impaired CagA translocation, an effect that 
was also evident in the Hp0305/Hp1564 double mutant 
(Figure 2(e)). In addition, H. pylori lacking Hp1564 
produced less CagA when co-cultured with gastric 
epithelial cells compared to bacteria grown in plank-
tonic culture (Figure 2(e)). Analysis of tyrosine- 
phosphorylated CagA (pY-CagA) and total CagA levels 
in AGS co-cultures by semi-quantitative densitometry 
reveled a significant decrease in the ratio of injected 
CagA compared to total CagA in Hp1564-deficient 
strains (Figure 2(f)). Complementation with an epi-
tope-tagged form of Hp1564 restored the ability to 
translocate CagA into host cells to levels comparable 
to the WT strain (Figure 2(f)).
To confirm the finding that loss of Hp1564 signifi-
cantly reduces CagA translocation independent of qua-
litative CagA tyrosine phosphorylation assays, we 
Figure 1. Hp0305 and Hp1564 seropositivity predict gastric inflammation. Pepsinogen I/II ratio by Hp0305/Hp1564 serostatus in (a) the 
overall study population and (b) by stomach condition. The pepsinogen I/II ratio was compared between Hp0305- and Hp1564- 
negative individuals (n = 165), and Hp0305- or Hp1564-positive (n = 130) as well as Hp0305 and Hp1564 dual-positive individuals 
(n = 251) by Wilcoxon rank-sum test (**, p < .01; ***, p < .001; ****, p < .0001). In (a), -, seronegative; +, seropositive; in (b), SG, 
superficial gastritis (n = 60); CAG, chronic atrophic gastritis (n = 166); IM, Intestinal metaplasia (n = 142); Ind Dys, Indefinite Dysplasia 
(n = 116); Dys, Dysplasia (n = 62).
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Figure 2. Immunostimulatory H. pylori proteins modulate cag T4SS activity. Levels of IL-8 induced by WT H. pylori and the 
corresponding Hp0305, Hp1564, and complemented mutants co-cultured with AGS gastric epithelial cells (a) and adult primary gastric 
epithelial cells (b) were quantified by ELISA. Data represent a minimum of three biological replicate experiments for each strain. 
(c) H.pylori were co-cultured with AGS gastric cells for 4 hours prior to gentamicin-protection assays and enumeration of the total 
adherent and intracellular bacterial colony forming units (CFU). (d) WT H. pylori and the indicated mutants were grown overnight prior 
to collection and cell density normalization. The levels of CagA and the cag T4SS structural component CagY were analyzed by 
immunoblot. Mutants lacking either Hp0305 or Hp1564 produced CagA and CagY at levels similar to the parental WT strain. (e) AGS 
gastric cells were co-cultured with WT H. pylori or the indicated mutant for 6 h. Levels of translocated tyrosine-phosphorylated CagA (α- 
PY99), total CagA (α-CagA), host cell cytoskeleton (α-β-tubulin), and total H. pylori (α-OMP) were assessed by immunoblot. (f) Semi- 
quantitative densitometry analysis was used to determine the levels of tyrosine phosphorylated CagA (pY-CagA) and total CagA for the
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established a quantitative CagA translocation system in 
which the E.coli TEM1 β-lactamase is translationally 
fused to the N-terminus of CagA (TEM-CagA) and 
expressed from the native locus driven by the endogen-
ous cagA promoter.19 Translocation of TEM-CagA into 
AGS cells is monitored via TEM β-lactamase-mediated 
cleavage of the TEM substrate CCF4-AM19 and deter-
mination of the ratio of blue (cleaved CCF4-AM) to 
green (intact CCF4-AM) fluorescence signal (Figure 2 
(g)). In order to determine if Hp1564 inactivation leads 
to a reduction in the levels of translocated CagA, we 
generated a mutant deficient in Hp1564 and the corre-
sponding complemented strain in the H.pylori 26695 
[TEM-CagA] background. As anegative control, we 
employed an isogenic H.pylori 26695 [TEM-CagA] 
cagE mutant in which an ATPase required for cag 
T4SS function is inactivated. Under standard infection 
conditions, H.pylori 26695 [TEM-CagA] translocated 
significantly more TEM-CagA into gastric epithelial 
cells compared to the corresponding cagE and 
Hp1564 isogenic mutant strains by 2.5 h of infection 
(Figure 2(h)). CagA translocation defects exhibited by 
the H.pylori 26695 [TEM-CagA] Hp1564 strain were 
rescued by complementation with an epitope-tagged 
Hp1564 (Figure 2(h)), corroborating our observation 
that Hp1564 mutants are associated with significantly 
reduced levels of tyrosine-phosphorylated CagA com-
pared to the WT strain (Figure 2(e,f)). Taken together, 
these results demonstrate that Hp1564 significantly 
influences CagA translocation into gastric epithelial 
cells.
Hp0305 and Hp1564 are regulated in response to 
gastric epithelial cells
In addition to the protein effector CagA, the cag T4SS 
has the capacity to deliver chromosomally-derived bac 
terial DNA to host cells to activate TLR9.8 In order to 
determine if Hp0305 or Hp1564 also influence cag 
T4SS-dependent TLR9 activation, a CagA transloca-
tion-independent phenotype, we employed a robust 
HEK293-hTLR9 reporter cell line.8 H. pylori deficient 
in either Hp0305 or Hp1564 induced high levels of 
TLR9 activation that were indistinguishable from the 
parental WT strain (Figure 3(a)). Interestingly, althou 
gh TLR9 activation was not dependent on either 
Hp0305 or Hp1564, H. pylori deficient in both Hp03 
05 and Hp1564 were internalized into HEK293- 
hTLR9 cells to a lesser extent than the WT strain, at lev 
els similar to the cagX mutant (Figure 3(b)). These da 
ta support our previous finding that Hp0305/1564 
mutants exhibit an adherence and internalization def 
ect when co-cultured with AGS gastric epithelial cells.
Lastly, to determine whether Hp0305 and Hp1564 
are regulated in response to host cell contact, we 
examined the levels of Hp0305 and Hp1564 mRNA 
produced by H. pylori that were co-cultured with pri 
mary gastric epithelial cells. Compared to mRNA leve 
ls produced by the inoculum, contact with primary 
gastric epithelial cells down-regulated the production 
of Hp0305 at 6- and 12-h post-infection in the WT 
strain (Figure 3(c)), while levels moderately increased 
in the cagX mutant strain by 12-h post-infection. In 
contrast, co-culture with primary gastric cells stimu-
lated the production of Hp1564 at 6- and 12-h post- 
infection (Figure 3(d)) in both strains. Compared to 
transcript levels observed in WT bacteria co-cultured 
with primary gastric epithelial cells, the expression of 
Hp1564 was significantly increased in the cagX mutant 
strain under the same conditions (Figure 3(d)). These 
data suggest that during early infection, H. pylori may 
up-regulate the expression of Hp1564 as a mechanism 
to stimulate cag T4SS activity. Taken together, our 
data demonstrate that Hp0305 and Hp1564 are linked 
to multiple cag T4SS-dependent phenotypes and drive 
key bacterial interactions with gastric cells.
indicated strains in a minimum of four biological replicate experiments. Graph depicts the ratio of translocated CagA to total CagA for 
each strain. (g) Schematic of quantitative TEM-CagA translocation assay. Production of the TEM-1 β-lactamase-CagA fusion protein 
(TEM-CagA) is driven by the cagA promoter from the endogenous locus. TEM-CagA translocation is monitored by a FRET-based assay in 
which CCF4 is loaded into AGS cells 2.5 hours post-infection. TEM-CagA translocation is determined by the ratio of cleaved CCF4 
(emission at 450 nm) compared to intact CCF4 substrate (emission at 520 nm). (h) AGS cells were infected with WT or the indicated 
mutant strain and were subsequently loaded with CCF4-AM. Turnover of CCF4 by translocated TEM-CagA was monitored by 
determining the ratio of substrate emission at 450 nm to the emission at 520 nm. Ratios were normalized to cell-free controls, and 
are expressed as the fold change over uninfected AGS cells. Statistical significance was determined by one-way ANOVA with Dunnett’s 
post-hoc correction for multiple comparisons in (a), (b), (f) and (h). In (c), enumerated CFUs for each mutant were compared to the WT 
strain by two-tailed Mann-Whitney test. (*, p < .05; **, p < .01, ***, p < .001, ****, p < .0001 compared to WT in all panels).
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Discussion
Our previous prospective studies in East Asia have 
demonstrated and further validated that seropreva-
lence to the uncharacterized H. pylori proteins 
Hp0305 and Hp1564 is significantly associated with 
gastric cancer risk.12,13 Here, we demonstrate that 
seroprevalence to these proteins is also associated 
with increased levels of gastric atrophy (evidenced by 
decreased pepsinogen I/II ratios), an established hall-
mark of gastric inflammation.
To further define the mechanism underlying the 
observation that seropositivity to Hp0305 and Hp1564 
is associated with gastric inflammation and gastric 
cancer risk, we conducted several in vitro studies 
employing H. pylori mutants deficient in Hp0305, 
Hp1564, or Hp0305/Hp1564. We demonstrate that 
Hp0305 and Hp1564 contribute, at least in part, to 
driving a robust inflammatory response in gastric 
epithelial cells. To pinpoint the role of these virulence 
factors in H. pylori-induced pathologies, we assessed 
whether Hp0305 or Hp1564 influence translocation of 
the oncoprotein CagA into host cells. Hp1564, but not 
Hp0305, is necessary for CagA translocation, while 
both genes are required for proper bacterial adhesion 
to host cells. Interestingly, TLR9 activation, a phenot 
ype dependent on cag T4SS activity, was not affected 
by the absence of either Hp0305 or Hp1564. These 
results suggest that loss of Hp1564 negatively impacts 
CagA translocation independent of additional cag T4 
SS-associated phenotypes, including the delivery of 
peptidoglycan and nucleic acid substrates to host cells.
Hp0305 is an immunogenic H. pylori membrane 
protein that harbors a YceI-like domain with homology 
to the lipocalin fold. Previous studies have shown that 
Hp0305 is a component of outer membrane vesicles 
(OMVs) produced in response to acidic stress condi-
tions such as those found in the stomach.22–24 As such, 
OMVs play a critical role in bacterial colonization, as 
well as delivery and translocation of bacterial virulence 
factors. Secreted OMVs are highly immuno genic, 
Figure 3. Hp0305 and Hp1564 are regulated in response to the gastric epithelium. (a) WT H. pylori and the indicated mutant strains 
were co-cultured with a HEK293 reporter cell line expressing human TLR9. Normalized levels of TLR9 activation are expressed as the 
fold change over the corresponding mock-infected cells. (b) H. pylori were co-cultured HEK293-hTLR9 cells for 4 hours prior to 
gentamicin protection assays and enumeration of the total adherent and intracellular bacterial colony forming units (CFU). H. pylori 
were co-cultured with human adult primary gastric epithelial cells, and levels of Hp0305 (c) or Hp1564 (d) transcript produced by the 
indicated strain was assessed at 6 h and 12 h post-infection. Target transcripts were normalized to the level of gyrB transcript produced 
by each strain, and transcript abundance was compared to the level of corresponding normalized transcript produced by H. pylori 
cultured in the absence of host cell contact. In (b), enumerated CFUs for each mutant were compared to the WT strain by two-tailed 
Mann-Whitney test. In (c) and (d), transcript levels produced by the cagX mutant were compared to WT by unpaired two-tailed t-test (*, 
p < .05; **, p < .01, ****, p < .0001 compared to WT in all panels).
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prompting production of pro-inflammatory cyt 
okine and activation of antigen-presenting cells, 
as well as induction of innate and adaptive 
immune responses.25 These observations regard-
ing H. pylori OMVs complement findings from 
the current study demonstrating the potential uti-
lity of antibody levels to Hp0305 in predicting 
gastric cancer risk in a cohort of East Asian 
individuals.12 Previous studies designed to char-
acterize Hp0305 have found that purified, reco 
mbinant Hp0305 binds multiple cell types includ-
ing gastric epithelial cells, macrophages, and 
neutrophils.23 Furthermore, recombinant 
HP0305 has been shown to induce apoptosis and 
TNF expression via ERK/MAPK/SFK signaling 
in macrophages.23
Similar to Hp0305, the H. pylori outer membrane 
protein Hp1564 has been repeatedly found in culture 
supernatants as well as the bacterial cell surface, 
suggesting that it is a secreted protein.22,24 In addi-
tion, similar to Hp0305, one study identified Hp1564 
partitioned within OMVs.26 Other in silico analyses 
uncovered Hp1564 homology to membrane-bound 
methionine transporters in other bacterial species, 
suggesting a role of this previously uncharacterized 
protein in amino acid metabolism.27
Although the treatment regimen for H. pylori infec-
tion is well established, universal “test and treat” strategies 
are not practical given the scale of infection prevalence, 
the increased risk of adverse effects of H. pylori eradica-
tion in individuals with less-virulent strains, and adher-
ence to antibiotic stewardship.4,28–33 As such, there is an 
urgent need to identify biomarkers that can specifically 
identify those patients at highest risk for gastric cancer 
(such as Hp0305 and Hp1564) for targeted eradication 
strategies. Our results strengthen previous population- 
based studies and delineate the mechanistic basis for their 
strong association with gastric cancer risk. Given the high 
prevalence of H. pylori colonization among individuals at 
risk for development of severe gastric disease, this work 
provides the framework for more efficacious treatment 
and prevention strategies that specifically target Hp0305/ 
Hp1564-regulated pathways.
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